## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Ross, Douglas D. et. al.

Application No.: 09/961,086

Filing Date:

September 21, 2001

Group Art Unit: 1642

Examiner: Susan Ungar

Confirmation No.: 6592

Title: Breast Cancer resistance Protein (BCRP) and the DNA which Encodes it

## **FOURTH** INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:							
	Enclosed is a <b>FOURTH</b> Informating 1449 for the above-identified patent application	ion Disclosure Statement and accompanying form n.					
	No additional fee for submission of an IDS	-					
 	The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.  A statement under 37 C.F.R. § 1.97(e) is also enclosed.						
ĺ		nd the fee of \$180.00 (1806) as set forth in 37 C.F.R.					
l	Charge to Deposit Account	No. 02-4800 for the fee due.					
[	A check in the amount of is Charge to credit card. For						
1.21	The Director is hereby authorized to charge and hat may be required by this paper, and to crecisaper is submitted in duplicate.	y appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and dit any overpayment, to Deposit Account No. 02-4800.					
		Respectfully submitted,					
		BURNS, DOANE, SWECKER & MATHIS, L.L.P.					
Alexa	Box 1404 ndria, Virginia 22313-1404 836-6620	By Janifer John Meller  (Jennifer A. Topmiller, Ph.D.					
Date:	April 13, 2004	Registration No. 50,435					

BURNS **DOANE** BURNS DOANE SWECKER & MATHIS LLP INTELLECTUAL PROPERTY LAW



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ross, Douglas D. et. al.

Application No.: 09/961,086

Filed: September 21, 2001

For: Breast Cancer resistance Protein (BCRP) and the DNA which Encodes it

Coroup Art Unit: 1642

Examiner: Susan Ungar

Confirmation No.: 6592

## FOURTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted before the first Office Action on the merits, (only a Requirement for Restriction has been issued). Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is believed to be required.

FOURTH Information Disclosure Statement Application No. 09/961,086
Attorney's Docket No. 028754-039
Page 2

To assist the Examiner, the document is / documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

42.3

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date April 13, 2004

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620 By: A Tomillar Db C

Registration No. 50,435

Substitute for form	1449A/PTO & 1449B/F	PTO	Complete if Known				
FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT							
			Filing Date	September 21, 2001			
			First Named Inventor	Ross, Douglas D. et. al.			
IPE	(use as many shee	ts as necessary)	Examiner Name	Susan Ungar			
Sheed 1 of 1		Attorney Docket Number					
1 3 2004			U.S. PATENT DOCUMENTS				
THANKETHOUT Document Kind Code (if known)		Name of Patentee or Applica of Cited Document	Issue/Publication Date (MM-DD-YYYY)				
	Sheed 1 3 2004	FOUR INFORMATION STATEMENT BY Sheet 1 of	INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)  Sheet 1 of 1  1 3 2004  Document Kind Code	FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)  Sheet 1 of 1  U.S. PATENT DOCUMENTS  Name of Patentee or Application Number  Filing Date First Named Inventor Examiner Name Attorney Docket Number	FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)  Sheet 1 of 1  U.S. PATENT DOCUMENTS  FOURTH Application Number 09/961,086  Filing Date September 21, 2  First Named Inventor Ross, Douglas II  Examiner Name Susan Ungar  Attorney Docket Number 028754-039  U.S. PATENT DOCUMENTS  Name of Patentee or Applicant		

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Document Kind Code Number (if known)	Kind Code	Country	Date of Publication	Translation			
		Country	(MM-DD-YYYY)	Yes	No			
	<u></u>							
_			11. 11. hg 11.					
					<b>.</b>			
					-			
		_			ļ			

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CHANG-JIE CHEN, ET AL., "Genomic Organization of the Human Multidrug Resistance (MDR1) Gene and Origin of P-glycoproteins", The Journal of Biological Chemistry, Vol. 265(1):506-514 (1999)			
	A. AUSTIN DOYLE ET AL., "Characterization of a 95 Kilodalton Membrane Glycoprotein Associated with Multi- Drug Resistance", Int. J. Cancer: 62:593-598 (1995)			
	L.A. DOYLE ET AL., "Expression of a 95 kDa Membrane Protein is Associated with Low Daunorubicin Accumulation in Leukaemic Blast Cells", Br. J. Cancer 1995 Jan.;71(1)52-8			
	D.D.ROSS ET AL., "Expression of Multidrug Resistance-Associated Protein (MRP) mRNA in Blast Cells from Acute Myeloid Leukemia (AML) Patients", Leukemia (1996) 10, 48-55			
	D.D.ROSS ET AL., "Susceptibility of Idarubincin, Daunorubicin, and Their C-13 Alcohol Metabolites to Transport-Mediated Multidrug Resistance", Biochemical Pharmacology, Vol. 50(10):1673-1683 (1995)			
-				

Examiner	Date				
Signature	Considered		 		
		0 000	 	 	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.